Session Chair Profile
Ph.D., Director, The Israel National Center for Personalized Medicine, Weizmann Institute, Rehovot, Israel
Previously Dr. Strulovici conducted postdoctoral research under the guidance of Professor Robert J. Lefkowitz at the HHMI Duke University Medical School in Durham, NC. Berta has a track record in building and leading outstanding, productive teams, while integrating innovative processes into seamless, successful enterprises in start-up and large Pharma environments. She served as Director R&D at Tularik, the first start-up focused on targeting transcription factors in disease. At Merck Research Laboratories (MRL) in North Wales, PA, Berta served in positions of increased responsibilities over a period of 12 years. As Vice President of Basic Research in charge of building a state-of-the-art Center of Excellence for early drug discovery for Merck Worldwide, she and her team were involved in the discovery of lead compounds that are currently in clinical trials for various diseases. In 2012, Berta established the G-INCPM with the mandate to develop and implement novel technologies in genomics, proteomics, bioinformatics and Chemical Biology to enable and advance Personalized Medicine and life sciences in Israel.
Integrated Technological Platforms to Advance Science and Medicine in Israel
The Nancy and Stephen Grand Israel National Center for Personalized Medicine (G-INCPM) at the Weizmann Institute brings together world-leading basic and clinical researchers from all over Israel. The unique strength of G-INCPM lies both in the integration of enabling-technology platforms and the strong ties with academic researchers, creating a scientific momentum that extends technological boundaries. This talk will highlight specific examples of complex projects that take advantage of our integrated infrastructure to enable a deeper understanding of the patient and their response to therapies, with the potential for a more personalized treatment.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: Precision medicine centers are now an integral part of research and medical institutions. However, they face many challenges as they integrate enabling-technology platforms to achieve throughput goals, build biological repositories, analyze data, or enable translational research. This session will reveal some of the challenges, solutions, observations and best practices that a number of these centers encounter.